drugset / Trial / NCT01119924

A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain

NCT01119924

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Efficacy and Safety of Smilon® in the Depression Patients with pain. Eligible patients will be randomly assigned to 1 of 2 arms, either Smilon® or placebo, and will receive the treatment for 8 weeks in this study.

Timeline

Start
2009-12
Primary completion
2010-08
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirtazapine Other / unclassified 30 mg

Indications